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AbstrAct
The 1,2-fucosyl-oligosaccharides, and among these the 2’-fucosyl-lactose (2’-
FL) and lacto-N-fucopentaose (LNFP)-I, are quantitatively the most represented 
oligosaccharides of human milk. They are also seen to represent an important 
immune device to prevent nursing infants from severe infectious diarrhoea. 
Recent evidences show that the appearance of 2’-FL and  LNFP-I in human colos-
trums is synchronised with the macrophage inhibition and that LNFP-III induces 
a Th2 response from the mouse peripheral immune system. Since mannosyl-fuco-
syl receptors are described on the macrophage surface, all these evidences allow 
us to investigate on the possible immune function of human 2’-FL and LNFP-I in 
vitro on LPS-activated mononuclear cells (MNC) from 12 patients with multiple 
sclerosis (MS) and 20 matched health controls (HC). We found that 2’-FL and 
LNFP-I significantly decrease, to a different extent, the MNC proliferation from 
both HC and MS patients, in a linear and dose-dependent manner. 2’-FL and LNFP-
I also reduce the production of IL-12 and IFN-γ, particularly in MS patients as 
compared to HC (p=0.01 and p<0.001, respectively), while increasing that of IL-
10. The overall immunomodulatory effect of 2’-FL and LNFP I here presented may 
represent a future therapeutic option for the abnormal immune response found in 
some monocyte-mediated diseases. 
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IntroductIon
Oligosaccharides are important constituents of the 
human milk representing its third largest component 
(from 7.90 to 16.71g/l) (1). Most human milk oligosaccha-
rides are fucosylated, their production varies in relation 
to maternal Lewis blood group type and their distribution 
changes dynamically during the different phases of lacta-
tion, following an a priori program selected to the neces-
sity of nursing infants (2). Among all fucosylated milk 
oligosaccharides, the α1,2-linked fucosylated glycans, 
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which require the secretor gene for expression in human 
milk, are the dominant glycan structure found in the milk 
of secretor mothers, who represent the majority (approxi-
mately 80%) of mothers worldwide (3). Despite oligosac-
charides were initially considered to be functionless, it has 
lately become apparent that at least some of them may pro-
tect infants against pathogens (2). The α1,2-linked fuco-
sylated glycans are the first appearing, the longest-lasting 
and the most active in preventing infants from diarrhoea 
(4-6). In vitro and in vivo studies have demonstrated that 
α1,2-linked fucosylated oligosaccharides inhibit bind-
ing by Campylobacter, E. coli toxin and viruses to their 
target host cell receptors (5, 6) through a competitive 
mechanism.
It has also become progressively clear that 1,2-fuco-
sylated milk oligosaccharides represent a component of 
an innate immune system by which the lactating mother 
protects her infant from environmental pathogens, partic-
ularly during the first months. Higher relative concentra-
tions of 1,2-linked fucosylated oligosaccharides in human 
milk are associated with protection of breast-fed infants 
against diarrhoea of all infectious causes (3). Viruses, bac-
teria and toxins may become pathogenic after adhering 
to receptors located on the surface of intestinal epithelial 
cells (2, 7). Thus, intestinal cells are covered with 1,2 fuc-
osylated glycoproteins and glycolipids (8, 9) produced by 
both epithelial cells and colonizing pathogens (10) which, 
through a host/pathogen protective molecular mimicry, 
prevent microrganisms from developing their full patho-
genic potential (11-13).
A mannosyl-fucosyl receptor is described on the sur-
face of macrophages (14). Perhaps not coincidentally, 2’-
fucosyl-lactose (2’-FL) and lacto-N-fucopentaose (LNFP)-
I, the first two appearing oligosaccharides in human 
colostrums (15), are synchronised with the concomitant 
macrophage deactivation, as demonstrated by the rapid 
decrease of colostrums chitotriosidase activity in the first 
three days of lactation (16). Interestingly, Okano and col-
laborators (17) have recently demonstrated the induction 
of a peripheral Th2 responses in mice by the immunisa-
tion with Schistosoma mansoni egg antigens, which was 
largely due to LNFP III, its predominant carbohydrate; the 
fucose residue of LNFP III was crucial for the immune 
response to rise. These results demonstrated that fucose-
containing carbohydrates can show an ability to induce a 
Th2 response.
With this background in mind, we tested the effect of 
2’-FL and of LNFP-I, both showing fucose residue in their 
extremities, on the proliferation and the cytokine produc-
tion of E. coli lipopolysaccharide (LPS)-activated mono-
nuclear cells from healthy subjects. As it cannot be a priori 
excluded that the potential immuno-modulatory effect of 
2’-FL and LNFP I may be due to the presence of lactose, 
control experiments in parallel by using lactose alone were 
also performed.
Mononuclear cells from multiple sclerosis (MS) 
patients were also included in this study. The rational for 
choosing such cells is based on the evidence that MS is 
a chronic inflammatory disease of the central nervous 
system. Despite adaptive T- and B-cell antigen-specific 
responses are advocated at its patho-physiological basis, 
a growing body of data indicates that the innate immune 
response predominates in most MS lesion subtypes, which 




Twenty health controls (HC), 8 males and 12 females, 
mean age 27 ± 3) and 12 patients with definite MS (4 males 
and 8 females, mean age 28 ± 3 years, mean disease dura-
tion 6 ± 3 years) were recruited for this study. All patients 
and controls gave written consent to participate to this 
study.
MNC cultures and oligosaccharides
According with worldwide adopted protocols, periph-
eral blood mononuclear cells (MNC) were obtained 
through a discontinuous density gradient as follows: hepa-
rinized blood was diluted 1:1 with PBS. Blood was lay-
ered on Ficoll (Lymphoprep; 1.077 g/ml; Nycomed, Oslo, 
Norway) at room temperature and centrifuged 30 min at 
3000 rpm (no brake). Peripheral blood mononuclear cells 
were collected through a glass pipette and washed twice 
in cold PBS to avoid monocyte elimination due to their 
spontaneous plastic adherence. MNC were then counted. 
RPMI 1640 (Gibco, Paisley, Scotland) was used as culture 
medium, supplemented with 2 mM L-glutamine, 1% non-
essential amino acids, 10% fetal calf serum, 50 U/ml peni-
cillin and 50 µg/ml streptomycin (all from Gibco). The 
presence of monocytes within the MNC pool was con-
firmed on day 3 of culture by flow cytometry as positive 
for CD14 and HLA-DR, but lacking the markers for CD3 
(T cells), CD19 and CD20 (B cells), CD16 and CD56 (NK 
cells), and CD123 (plasmocytoid DC). After 3 days the 
viability of the cultured cells was assessed through the use 
of the Turk’s reagent. More than 90% of cells were living 
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at that time and available for the subsequent experiments.
A preliminary experiment, represented on Figure 1, was 
designed to obtain the concentration of 2’FL to be added 
on LPS-activated MNC and to test the virtual inefficacy 
of a largely represented milk disaccharide such as lactose. 
For this preliminary test MNC from 6 HC were plated on 
a 96-well plate (200,000 MNC/well), either kept alone (3 
wells/subject; white figures on Figure 1) or added with LPS, 
10 µg/ml (filled figures on Figure 1). LPS-stimulated cells 
were either kept alone (3 wells/subject), added with 2’-FL 
in triplicate, at the physiological concentrations of 5, 10, 
20, 30, 50 and 100 µg/ml (filled triangles) or pulsed with 
lactose, in triplicate, at the same concentrations as for 2’-
FL (filled circles). With the significant response obtained, 
the 2’-FL concentration of 30µg/ml (0.06mM) was used 
(See also Results section). Subsequently, 2’ FL and LNFP 
I (all by Sigma-Aldrich ns. ref. F 0393 and L 5908) were 
diluted in RPMI, both at an equimolecular concentration 
corresponding to 30µg/ml 2’-FL (0.06mM) and used for 
the proliferation and cytokine tests. 
Proliferation assay
MNC from 20 HC and 12 MS were plated on a 96-well 
plate (200,000 MNC/well), either kept alone (3 wells/sub-
ject) or added in triplicate with 10 µg/ml LPS; then hydro-
cortisone (21,7 µg/ml; 0.06 mM) and equimolar amounts 
of 2’-FL (30 µg/ml), LNFP-I (51.2 µg/ml), and lactose 
(21.6 µg/ml), were added. A control experiment was made 
using placebo (i.e saline solution). After 48 hours, cell 
cultures were harvested, transferred in another 96-well 
microtiter plate and incubated with BrDU. After an addi-
tional 3 h culture, a proliferation assays was performed, in 
triplicate. Following instructions from the manufacturer 
(Amersham Biosciences) standard curves were performed 
for each assay. Optical density (OD) was measured using 
an enzyme-linked immunosorbent assays (ELISA) reader. 
According with the manufacturer indications, OD value 
of 1 is equivalent to 20 (3H)-thymidine cpm × 103  in a 
proliferation test of 24h duration and 500 L929 cell/well 
concentration.
Cytokine production from MNC  
On the proliferation test culture supernatants, techni-
cians blind to clinical information performed the ELISA 
analysis for human IL-10, IL-12p40, TNF-α and IFN-γ (all 
from Euroclone, Switzerland). All assays for both stand-
ards and samples were performed in triplicate on 96-well 
plates, according with indications and suggestions from 
the manufacturers, and standard curves of the relationship 
between optic density and molecular concentration calcu-
lated accordingly. Biomarkers were expressed as pg/ml.
Statistics
The results were reported as mean and standard devia-
tion (SD). Differences between MNC proliferations in dif-
ferent conditions (expressed as optic density) were ana-
lysed by using a two-tailed paired and unpaired T-test. 
Significance level (p) was conventionally set at <0.05.
results
Proliferation assay in untreated and LPS-activated 
MNC
The mean proliferation of all untreated MNC was 3.6 
± 0.8 OD. When stratifying results according with health 
status, the mean proliferation was 3.4 ± 0.7 in MS patients 
and 3.8 ± 0.8 in HD (p not significant); no significant 
anti-proliferative effect was observed with the addition of 
either 2’-FL or lactose at either low or high concentrations 
(Figure 1, white triangles and circles). On the contrary, 
Figure 1. Dose-dependent and linear effect (±SD) 
of 2’-fucosyl-lactose (black triangles) and lactose 
(black circles) on LPS-driven MNC proliferation. On 
Y axis the proportion of the LPS-induced MNC pro-
liferation (filled figures) compared to the unstimu-
lated MNC (white figures). On X axis the concen-
tration (µg/ml) of 2’-fucosyl-lactose and lactose 
in the MNC culture plates. The dose-dependent 
effect of 2’-fucosyl-lactose (white triangles) and 
lactose (white circles) on unstimulated MNC are 
also represented. 
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the mean proliferation of the LPS-stimulated MNC was 
6.1 ± 2.4 OD in MS patients and 5.9 ± 1.2 in HC, which 
was significantly higher (157.9%, p=0.002) as compared to 
untreated cells but not significantly different between the 
two groups (data not shown).
Effect of 2’FL and lactose on MNC proliferation (titra-
tion experiment, Figure 1)
2’-FL at the concentrations of 5, 10, 20, 30, 50 and 
100 µg/ml inhibited LPS-driven MNC proliferation by, 
on average, 2.6% (p not significant), 15.6% (p not signifi-
cant), 18.8% (p not significant), 23.4% (p=0.002), 22.7% 
(p=0.002) and 25.3% (p<0.001), respectively. This dose-
dependent effect was linear. The 2’-FL concentration of 
30 µg/ml (0.06mM/L) was chosen for the remaining tests 
to be performed. On the contrary, lactose induced a slight 
and not significant increase of the LPS-driven MNC pro-
liferation in this preliminary test, as shown on Figure 1. 
In details, lactose at the concentrations of 5, 10, 20, 30, 50 
and 100 µg/ml increased the LPS-dependent MNC prolif-
eration of 0.6, 2.6, 3.2, 3.9, 7.1 and 10.4% (p not significant 
for all concentrations), respectively. These results suggest 
that lactose has neither proliferative nor osmotic effects on 
MNC, since the MNC proliferation remained substantially 
unmodified while increasing the lactose concentrations.
Overall effect of 2’-FL, LNFP-I, lactose and hydrocorti-
sone on LPS-pulsed MNC in MS and HC subjects
When LPS-pulsed MNC from both MS and HC were 
added with lactose, 2’-FL, LNFP-I and hydrocortisone 
(at equimolecular amount of 0.06 mM) we observed a 
decrease of MNC proliferation (Figure 2). The effect of 
the add-on chemicals was expressed as percentage com-
pared to LPS-treated MNC proliferation (assuming it as 
100%; Figure 2).
Lactose induced a reduction of the LPS-driven prolif-
eration of approximately 9% (from 100%, i.e. no effect, up 
to 91 ± 12%, i.e. 9% decrease; p= not significant); 2’-FL 
reduced the LPS-driven proliferation of 18 % on average 
(82 ± 16% of LPS-induced proliferation; p=0.04); LNFP-I 
decreased the LPS-driven proliferation of 26% on aver-
age (74 ± 11%: p=0.002) whilst hydrocortisone did it of 
approximately 34% (66.3 ± 8.7%; p=0.0002); significant 
differences were found between oligosaccharides them-
selves (LNFP-I vs. 2’-FL p=0.039), between oligosaccha-
rides (LNFP-I and 2’-FL) and lactose (p=0.02 and 0,04 
respectively) and, obviously, between oligosaccharides 
and steroid (hydrocortisone vs. LNFP-I: p=0.04; hydro-
cortisone vs. 2’-FL: p=0.038).
The effect of 2’-FL, LNFP-I, hydrocortisone and lac-
tose was not significantly different when stratified accord-
ing with health status (HC vs. MS) suggesting that 2’-FL, 
LNFP-I and hydrocortisone inhibit the MNC proliferative 
response to LPS independently from the MNC origin (data 
not shown).
Measurement of soluble MNC products (details on Table 
1 and Figure 3)
In untreated MNC, the baseline level of cytokine pro-
duction was similar between MS and HC. Also, LPS-stim-
ulated MNC from both HC and MS patients produced sig-
Figure 2. Effect of lactose, 2’-fucosyl-lactose 
(2’-FL), lacto-N-fucosyl-pentaose (LNFP)-I and 
hydrocortisone (cort) on the LPS-driven MNC pro-
liferation. On Y axis the proportion of the MNC pro-
liferation (100% is the level of the LPS-driven MNC 
proliferation). Lactose decrease LPS-driven MNC 
proliferation from 100 up to 91 ± 12% (p= not sig-
nificant); 2’-FL up to 82±16% (*p=0.04); LNFP-I up 
to 74 ± 11% (**p=0.002) and hydrocortisone (cort) 
up to 66.3 ± 8.7% (***p=0.0002); differences were 
also found between oligosaccharides (LNFP-I vs. 
2’-FL p=0.039), between oligosaccharides (LNFP-I 
and 2’-FL) and lactose (°p=0.02 and 0,04 respec-
tively) and between oligosaccharides and the ste-
roid (hydrocortisone vs. LNFP-I: p=0.04; vs. 2’-FL: 
p=0.038).
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nificantly higher levels of cytokines as compared to their 
untreated counterpart (p<0.01 for all cytokines), which did 
not significantly differ between the two groups. The treat-
ment of the LPS-driven MNC with equimolecular dose 
of 2’-FL, LNFP-I and hydrocortisone 1µg/ml reduced the 
production of the cytokines TNF-α, IL-12p40 and IFN-γ, 
as indicated on Table 1, whilst the treatment with equimo-
lar doses of lactose did not influence the overall cytokine 
secretion. The inhibitory effect of 2’-FL and LNFP-I on IL-
12p40 and IFN-γ production was particularly pronounced 
in the MS-derived MNC which significantly differed from 
the HC counterpart (p=0.01 for IL-12 and p<0.001 for 
IFN-γ after the use of 2’-FL; p=0.01 for both IL-12 and 
IFN-γ after the use of LNFP-I; (see Table 1). IL-10 produc-
tion was elevated after pulsing LPS-activated MNC with 
2’FL, LNFP-I and hydrocortisone but did not significantly 
differ between MS and HC (see Table 1 and Figure 3).
dIscussIon
In our study we found clear evidences that the two milk 
oligosaccharides 2’-FL and LNFP-I, used in a concentra-
tion which could be considered physiological, negatively 
influenced MNC activation by decreasing their prolifera-
tion in a dose-dependent fashion; 2’-FL and LNFP-I also 
have an inhibitory role on IFN-γ and IL-12 production in 
vitro, particularly in MS patients, and a pro-releasing effect 
on the Th2 cytokine IL-10. Thus, these two oligosaccha-
rides display an immunomodulatory effect, in vitro.
The results here described may reflect a cascade of 
events occurring within different MNC subpopulations 
(monocyte/macrophages, T-cell and others) which can 
be initiated by the 2’-FL and LNFP-I inhibitory effect 
on macrophages through the fucosyl receptor described 
on their surface (14). The two oligosaccharides induced 
a monocyte-macrophage down-regulation able of lower-
ing the production of the macrophage-derived cytokines 
such as IL-12 and TNF. They might also indirectly reduce 
the macrophage-mediated T-cell proliferation and IFN-γ 
production. In order to shed some lights on this intriguing 
point, we have planned future studies on whether 2’-FL 
and LNFP-I may have inhibitory actions on purified popu-
lations of immune cells (e.g. T cells, B cells, monocytes). 
We used the 2’ FL and LNFP-I 1,2-linked fucosyl-oli-
gosaccharides compared to lactose for several reasons. 
1,2-linked fucosyl-oligosaccharides are the first appear-
ing oligosaccharides in colostrums in the first three days 
of lactation (15), quantitatively the most represented and 
the longest-lasting (2-6). Moreover, a role for the 1,2-fuco-
syl oligosaccharide LNFP III in inducing a Th2 switch in 
peripheral immune cells of mice is also documented. For 
all such reasons we omitted the use of oligosaccharides 
with other fucose residue linkage (1-3, 1-4).
Besides being the main disaccharide contained in breast 
TABLE 1. Production of cytokines from untreated and LPS-stimulated MNC of MS patients and health controls 
(HC). After pulsing with lactose, 2’-FL, LNFP-I and hydrocortisone, LPS-stimulated MNC decreased the TNF-α, 
IL-12, and IFN-γ production and increased the IL-10 production as compared to the unpulsed LPS-treated MNC. 
Following 2’-FL- and LNFP-I pulse the effect is significantly higher for IL-12 and IFN-γ from MS compared to the 
HC counterpart. All values are expressed as mean pg/ml± standard deviation
Untreated MNC LPS (a) Lactose 2’-FL (b) LNFP-I (c) Hydrocortisone (d,e)
MS HC MS HC MS HC MS HC MS HC MS HC
TNF-α 120±62 115±62 351±85 379±75 324±72 329±68 268±85 249±75 248±65 240±75 155±62 146±52
IL-12p40 53±12 49±4 174±115 123±80 156±80 119±91 61±11* 97±40 55±12* 92±42 51±10 46±6
IFN-γ 26±7 30±11 143±43 190±40 135±25 141±66 32±23** 142±42 21±9** 65±30 12±4 15±3
IL-10 4.7±5 3.9±4 89±52 96±53 75±46 90±45 97±48° 112±64° 121±62 126±51 269±92 285±87
*IL-12 production: 2’-FL-treated MNC: MS vs. HC p=0.01; LNFP-I-treated MNC: MS vs. HC p<0.01. ** IFN-γ 
production: 2’-FL-treated MNC: MS vs. HC p<0.001; LNFP-I-treated MNC: MS vs. HC p=0.01. a= LPS-treated vs. 
untreated MNC: p<0.01 for all cytokines; b=2’FL- vs. LPS-treated MNC: p<0.05 for all cytokines with the excep-
tion of IL-10 (°p= not significant); c=LNFP-I- vs. LPS-treated MNC: p<0.05 for all cytokines; d=Hydrocortisone- 
vs. LPS-treated MNC: p<0.01 for all cytokines. e=Hydrocortisone- vs. 2’-FL and LNFP-I-treated MNC: p<0.05 for 
all cytokines.
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milk, lactose is a constitutive part of both 2’-fucosyllac-
tose and lacto-N-fucopentaose-I. Virtually, we could not 
exclude a priori that the immunomodulatory effect seen 
for 2’-fucosyllactose and lacto-N-fucopentaose-I may be 
due to the presence of lactose. To test the specificity of 
the fucose-mediated effect, we have carried out parallel 
experiments by using lactose alone which turned out to 
induced minimal and not significant immune effects on 
LPS-treated MNC. 
We are aware of the fact that other ligands of the man-
nose-fucose receptors are known to modulate the respi-
ratory burst response of macrophages (19). Also, the dif-
ferent content of 2’ FL and LNFP-I in the milk reflects 
distinct activity of the fucosyl-transferase of the mothers 
and up to 10 % Caucasian population lacks the 2’ fucosyl 
transferase (20).
In conclusion, we show for the first time that 2-FL 
and LNFP-I bear a novel immunomodulating function 
able to reduce the proliferation and detrimental cytokine 
production from peripheral lymphocytes through a mac-
rophage-mediated inhibition. The specificity of this reac-
tion, seems to be related to the characteristic structures 
of 2’FL and LNFP-I, both having the same terminal 
Fuc∝1-2ß Gal moiety. Comparing the model structures 
of these two oligosaccharides with Sweet, a program for 
constructing 3D models of saccharides (see website at 
http://www.dkfz.de/spec/sweet/doc/index.php), it appears 
that Fuc∝1-2ß Gal motive has the same conformation in 
each oligosaccharides.
Theoretical implications related to the present study are 
possible in the light of the current literature. The increase 
of cytokines such as IL-12 and IFN-γ play a determinant 
role in the complex cascade of events leading to the imbal-
ance toward a detrimental Th1 environment in MS (21): 
IL-12 p40 mRNA level in unstimulated MNC increases 
in MS patients compared with controls (22), whilst MS 
patients experiencing a relapse have significantly increased 
IFN-γ production after mitogen-driven MNC stimulation 
compared to patients in remission, which is reduced after 
treatment with IFN-β (23). Furthermore, the therapeutical 
effect of IFN-β in MS is strictly associated to its enhanc-
ing effect on IL-10 (24). 
Given their potential of opening a new avenue of thera-
peutic options in monocyte-mediated diseases, we think 
our findings warrant further evaluations.
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